ALFA Finder| Revenue growth | 31% YoY growth to INR 1,897.5 Mn. |
|---|---|
| Margins | EBITDA margin dropped to 25% from 35.6% YoY. |
| Demand visibility | Steady demand seen in LATAM and Europe for ADHD products. |
Growth
Revenue grew 31% YoY. However, EBITDA declined 8% and PAT fell 31% YoY due to higher operating expenses.
Outlook
Capacity expansion with new production blocks at Lote and Ambernath; targeting 3-4 new product launches annually.
Risks
Significant margin contraction (EBITDA margin down 1,063 bps YoY) and increased cost of goods sold.
Last quarter's promises, checked
Delivered
- Guided ~20% FY26 revenue growth → delivered 18.9% (~INR 828 Cr) (= BEAT)
- Guided 33%-35% EBITDA margin → delivered 35.5% (= BEAT)
- Guided 3-4 new product launches annually → delivered 4 launches in FY26 (= BEAT)
Partly delivered
- Guided INR 1,000 Cr revenue by FY27 → Q1 FY27 at INR 189.75 Cr (requires steep ramp-up) (= PARTIAL)
- Guided H2 FY27 launch for contrast media → development ongoing for enhanced economics (= PARTIAL)
Missed
- Guided 33%-35% EBITDA margin maintenance → delivered 25% in Q1 FY27 (= MISS)
Investor Presentation filed with NSE, NSE: SUPRIYA. Summary written with AI assistance from the document.
Supriya Lifescience Ltd: key numbers
- Share price
- ₹632.10
- Market cap
- ₹5,087 Cr
- Revenue (annual)
- ₹827.9 Cr
- Net profit (annual)
- ₹209.1 Cr
- P/E (TTM)
- 28.7×Sector 43.7×
- Promoter holding
- 68.30%+0.00% QoQ
- FII holding
- 6.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Supriya Lifescience Ltd
All →Supriya Lifescience Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹206 Cr (+3.2% YoY), EBITDA ₹45 Cr (-37.5%), margin 22%. LATAM regulatory shock, Ambernath ramp-up costs and raw material inflation hit margins; FY27 margin guidance cut to 23–25%.
- Call
- Guides 20% growth
Supriya Lifescience Results Update
Supriya Lifescience's Q2 FY27 revenue rose 3.2%, but EBITDA and PAT fell sharply. Ambernath ramp-up costs and LATAM regulatory shifts hurt margins.
Supriya Lifescience Q2 FY27 Results: Net Profit ₹29.2 Cr, Down 42.1% YoY
Supriya Lifescience Ltd reported revenue from operations of ₹206.3 Cr (+3.3% YoY) and net profit of ₹29.2 Cr (-42.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹29.2 Cr · -42.1% YoY
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed that its General Manager, Sales & Marketing, was granted bail in an NDPS Act case. The company says the order has no material impact.
Supriya Lifescience Board Meeting Date
Supriya Lifescience will hold a board meeting on 6 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after results are declared.
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed a pending case was admitted by the Supreme Court. An interim order precludes coercive action against directors while the matter is sub judice.